Arrowhead Pharmaceuticals, Inc.
ARWR
$82.63
-$2.48-2.91%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -46.38% | -530.79% | 229.73% | 86.45% | -147.31% |
| Total Depreciation and Amortization | 4.57% | -0.34% | 0.06% | 2.62% | 2.28% |
| Total Amortization of Deferred Charges | 16.59% | -- | -- | -- | -- |
| Total Other Non-Cash Items | 149.64% | -42.23% | -50.05% | 136.27% | -15.11% |
| Change in Net Operating Assets | -124.19% | 404.49% | -61.09% | -113.59% | -139.45% |
| Cash from Operations | -310.17% | 526.38% | -34.21% | 113.24% | -133.63% |
| Capital Expenditure | -50.25% | -19.41% | 71.32% | -216.79% | 55.37% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 105.33% | -4,029.47% | -126.96% | -44.27% | 134.65% |
| Cash from Investing | 104.88% | -3,666.67% | -132.69% | -48.64% | 133.65% |
| Total Debt Issued | -100.00% | -- | -- | -55.45% | -- |
| Total Debt Repaid | -87.28% | 73.27% | -- | 100.00% | 67.02% |
| Issuance of Common Stock | -77.58% | 162.61% | 10,142.60% | 127.35% | -99.91% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 110.36% | -- | -- | -- | -- |
| Cash from Financing | -100.06% | 5,494.69% | -502.02% | 108.60% | -146.20% |
| Foreign Exchange rate Adjustments | -52.16% | 840.57% | 541.67% | -125.81% | 123.13% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -919.03% | 47.30% | -125.74% | 273.04% | -142.42% |